Adocia SA announced new positive results for BioChaperone®Lispro insulin (named THDB0206 in China) with partner Tonghua Dongbao. BioChaperone Lispro was compared with Humalog (insulin lispro) and pharmacokinetic/pharmacodynamic properties of BioChaperone Lispro were significantly faster. Moreover, BioChaperone Lispro confirmed its good tolerability and safety profiles.

Conducted in parallel of the Phases 3, this Phase 1 study was conducted in an open label, positive control, randomized, crossover trial to evaluate pharmacokinetics and pharmacodynamics of single dose of BioChaperone Lispro in healthy Chinese volunteers. The primary objective of this study was to evaluate whether a BioChaperone Lispro injection has a faster absorption and onset of action compared to an insulin Lispro injection. Adocia licensed BioChaperone Lispro to Tonghua Dongbao for China and major Asian territories that represents 200 million people suffering from diabetes, with an estimated 20 million using insulin daily for their survival.